Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Laboratory investigation; a journal of technical methods and pathology - 1 Nov 2013

Bozzi Fabio, Conca Elena, Laurini Erik, Posocco Paola, Lo Sardo Alessandra, Jocollè Genny, Sanfilippo Roberta, Gronchi Alessandro, Perrone Federica, Tamborini Elena, Pelosi Giuseppe, Pierotti Marco A, Maestro Roberta, Pricl Sabrina, Pilotti Silvana

Abstract excerpt

The molecular marker of well-differentiated/de-differentiated liposarcomas is MDM2 gene amplification coupled with protein overexpression and wild-type TP53. MDMX is a recently identified MDM2 homolog and its presence in this tumor is unexplored. Our aim was to investigate the role of full-length...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to Gene Dosage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Liposarcoma

Share to Molecular Dynamics Simulation

Share to Piperazines

Share to Protein Isoforms

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 24018792
DOI: 10.1038/labinvest.2013.107

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24018792-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.PMID 24018792Read ↗

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.Semantic proximity Read ↗

Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated LiposarcomaSemantic proximity Read ↗

MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of actionSemantic proximity Read ↗

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.Semantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

A Rapid and Cost-Effective Gene Expression Assay for the Diagnosis of Well-Differentiated and Dedifferentiated LiposarcomasSemantic proximity Read ↗

Clinical and Molecular Spectrum of LiposarcomaSemantic proximity Read ↗

High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.Semantic proximity Read ↗

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaSemantic proximity Read ↗

Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcomaSemantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

Prognostic Implications of MDM2 and CDK4 Co-amplification in Liposarcoma: Insights from FISH analysis for Translational OncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.